| Journal | Israel journal of health policy research |
| Study Type | Clinical Study |
| Population | Human participants |
This study examines user preferences between disposable and non-disposable e-cigarettes across two countries with different regulatory frameworks. Understanding these patterns is clinically relevant as many patients use e-cigarettes for tobacco harm reduction, and disposable bans could affect access to potentially less harmful alternatives to combustible tobacco.
Cross-sectional survey of 410 adults aged 18-45 in the U.S. and Israel who reported past 30-day e-cigarette use, with 62.9% using non-disposable devices. The study used multivariate logistic regression to identify factors associated with disposable versus non-disposable use patterns. Key finding showed that in Israel, greater perceived harm of e-cigarettes was associated with disposable use, suggesting different risk perceptions may drive device selection. The study provides policy-relevant data as several countries consider or have implemented disposable e-cigarette bans.
“While this study addresses an important policy question, it doesn’t directly inform my clinical decision-making since I focus on medical cannabis rather than nicotine products. However, the harm reduction framework and patient preference data are conceptually relevant to how we approach any substance used for therapeutic purposes.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What’s the difference between disposable and non-disposable e-cigarettes in terms of harm reduction potential?
- How might proposed bans on disposable e-cigarettes affect patients using them for tobacco cessation?
- Are there geographical differences in how adults choose between disposable and non-disposable e-cigarettes?
- What factors should clinicians consider when discussing e-cigarette device types with patients?
- How reliable is this evidence for making clinical recommendations about e-cigarette device types?
FAQ
What’s the difference between disposable and non-disposable e-cigarettes in terms of harm reduction potential?
This cross-sectional study found that 62.9% of adult e-cigarette users preferred non-disposable devices, suggesting these may offer better long-term harm reduction benefits. Non-disposable devices typically allow for more controlled nicotine delivery and customization, which may be important factors for adults transitioning away from traditional cigarettes.
How might proposed bans on disposable e-cigarettes affect patients using them for tobacco cessation?
The study indicates that disposable e-cigarette bans could impact adults currently using these products for harm reduction purposes. Understanding usage patterns is essential for policy development to ensure that regulations don’t inadvertently harm individuals who rely on these devices as a less harmful alternative to traditional tobacco products.
Are there geographical differences in how adults choose between disposable and non-disposable e-cigarettes?
Yes, the study found country-specific differences between U.S. and Israeli users, with perceived harm levels influencing device choice differently in Israel compared to the U.S. These cultural and regulatory differences suggest that clinical recommendations may need to consider local contexts and patient populations.
What factors should clinicians consider when discussing e-cigarette device types with patients?
Based on this research, clinicians should assess patients’ harm perceptions, usage patterns, and individual preferences when discussing e-cigarette options. The study suggests that patient choice between disposable and non-disposable devices may be influenced by multiple personal and environmental factors that warrant individualized consideration.
How reliable is this evidence for making clinical recommendations about e-cigarette device types?
This study represents early-stage evidence requiring further validation before clinical action, as indicated by its “monitored relevance” classification. While it provides useful insights into user preferences and patterns, clinicians should await additional research before making definitive recommendations about optimal device types for harm reduction or cessation purposes.